| Ytd | -37.46% | |
| 1y | -58.54% |
| Open | 0.68 | Prev Close | 0.70 | Low | 0.68 | High | 0.85 | Mkt Cap | 33.13M |
| Vol | 533.97K | Avg Vol | 149.70K | EPS | -0.85 | P/E | N/A | Forward P/E | -4.31 |
| Beta | 0.97 | Short Ratio | 1.28 | Inst. Own | 51.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 0.74 | 200-d Avg | 0.87 | 1yr Est | 9.20 |
TELA News
TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology
TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology
Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency pr
TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Es
TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.20) per share which missed the analyst conse
MALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commer
TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology
MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a comm
MALVERN, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commer
MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commer
Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-m
TELA Bio, Inc. (TELA) Q1 2026 Earnings Call Transcript
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus E
TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.21) per share which missed the analyst conse
MALVERN, Pa. , May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medi
MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commerc
MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage med
MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a comme
Citizens analyst David Turkaly maintains TELA Bio (NASDAQ:TELA) with a Market Outperform and lowe
TELA Bio (NASDAQ: TELA) reported fourth-quarter and full-year 2025 results that management character
TELA Bio, Inc. (NASDAQ: TELA) reported mixed results for the fourth quarter on Tuesday.
TELA Bio (NASDAQ:TELA) reported mixed Q4 results, with higher losses but lower sales than expected.
Top analysts change outlook for top names. Citigroup, Tigress Fin, Piper Sandler, Morgan Stanley, HC
Piper Sandler analyst Matt O'Brien maintains TELA Bio (NASDAQ:TELA) with a Neutral and lowers
Lake Street analyst Frank Takkinen maintains TELA Bio (NASDAQ:TELA) with a Buy and lowers the pri
Canaccord Genuity analyst Caitlin Roberts maintains TELA Bio (NASDAQ:TELA) with a Buy and lowers
TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus E
TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.17) per share which beat the analyst consens
MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage med
TELA Bio, Inc. (NASDAQ: TELA - Get Free Report) has received an average rating of "Hold" from the fi
TELA Bio is suing Becton Dickinson for allegedly abusing its monopoly power in the hernia mesh marke
